This is a snippet of the transcript, sign up to read more.
Three things are happening. First, with Foundation IP, law firms are increasingly handing over the annuity business directly to IP vendors. They don't want the liability, so they prefer to give it to someone like Clarivate or others. When they have a client, they might say, "We work with Clarivate with our IPMS, so you can work with them if you'd like, but be aware there are other options." Most of the time, corporations do an RFP or an informal consultation.
This is a snippet of the transcript, sign up to read more.
The second thing is Memotech. When you decide to discontinue an IPMS, there's a high likelihood that clients will run a new consultation or RFP. There's no reason to choose IPFolio without consulting the market, even if they feel more comfortable with Clarivate because they know the process and team. At the end of the day, it's like changing your entire IPMS, so why not check out what's going on outside?
This is a snippet of the transcript, sign up to read more.
Exactly, exactly the same. What's happening as well is that Clarivate is switching internally from CPA to IPAN because the annuities platform behind Memotech is CPA, but behind IPFolio, it's IPAN. I can tell you, this is not the same operation at all, and it's not the same quality either. The market is not blind to this; they have understood it.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research